BACKGROUND: Preoperative opioid use has been shown to increase postoperative opioid use following total knee arthroplasty (TKA). Tramadol is recommended for symptomatic treatment of osteoarthritis; however, it acts on opioid receptors and may confer similar adverse effects. The purpose of this study is to assess postoperative opioid use with preoperative opioid and tramadol use. METHODS: Patients undergoing primary TKA were identified in the Humana administrative claims database. Patients were stratified by whether they filled a prescription for an opioid, tramadol, either, or neither within 3 months of TKA. Prescription claims were tracked for 12 months postoperatively and relative risk for each group was calculated. RESULTS: In total, 107,973 patients undergoing TKA were identified. Preoperatively, 29,890 (27.7%) patients filled a prescription for opioids, 8049 (7.5%) for tramadol, 44,403 (41.1%) for tramadol or opioids, and 63,570 (58.9%) did not fill a prescription for either. At 12 months postoperatively, an opioid prescription was filled by 6.0% of preoperative narcotic-free patients, 35.2% opioid users (relative risk [RR] 5.83 [5.63-6.03]), 9.2% tramadol users (RR 1.52 [1.40-1.63]), and 29.5% opioid or tramadol users (RR 4.88 [4.72-5.05]). Opioid or tramadol prescriptions were filled by 7.7% of preoperative narcotic-free patients, 37.3% opioid users (RR 4.84 [4.70-4.99]), 26.2% tramadol users (RR 3.40 [3.26-3.57]), and 35.7% opioid or tramadol users (RR 4.64 [4.50-4.78]) at 12 months. CONCLUSION: Patients taking tramadol preoperatively were found to be at lower risk for prolonged postoperative opioid use following TKA. Patients taking either narcotics preoperatively continued use of these medications at a higher rate than those who were not.
BACKGROUND: Preoperative opioid use has been shown to increase postoperative opioid use following total knee arthroplasty (TKA). Tramadol is recommended for symptomatic treatment of osteoarthritis; however, it acts on opioid receptors and may confer similar adverse effects. The purpose of this study is to assess postoperative opioid use with preoperative opioid and tramadol use. METHODS:Patients undergoing primary TKA were identified in the Humana administrative claims database. Patients were stratified by whether they filled a prescription for an opioid, tramadol, either, or neither within 3 months of TKA. Prescription claims were tracked for 12 months postoperatively and relative risk for each group was calculated. RESULTS: In total, 107,973 patients undergoing TKA were identified. Preoperatively, 29,890 (27.7%) patients filled a prescription for opioids, 8049 (7.5%) for tramadol, 44,403 (41.1%) for tramadol or opioids, and 63,570 (58.9%) did not fill a prescription for either. At 12 months postoperatively, an opioid prescription was filled by 6.0% of preoperative narcotic-free patients, 35.2% opioid users (relative risk [RR] 5.83 [5.63-6.03]), 9.2% tramadol users (RR 1.52 [1.40-1.63]), and 29.5% opioid or tramadol users (RR 4.88 [4.72-5.05]). Opioid or tramadol prescriptions were filled by 7.7% of preoperative narcotic-free patients, 37.3% opioid users (RR 4.84 [4.70-4.99]), 26.2% tramadol users (RR 3.40 [3.26-3.57]), and 35.7% opioid or tramadol users (RR 4.64 [4.50-4.78]) at 12 months. CONCLUSION:Patients taking tramadol preoperatively were found to be at lower risk for prolonged postoperative opioid use following TKA. Patients taking either narcotics preoperatively continued use of these medications at a higher rate than those who were not.